Not provided
Not provided
Not provided
Not provided
difficulties of enrollment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to describe asthma phenotype with small airways dysfunction, in a multiparametric manner, with clinical, biological, morphological and genetic elements compared with asthma with proximal airways obstruction.
The objective of this study is also to complete the clinical, immunobiological and morphological analysis of asthma with small airways dysfunction.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| asthma with proximal or diffuse lung damage | Active Comparator |
| |
| asthma with small airway prevailing damage | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements. | Genetic | symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test. |
| Measure | Description | Time Frame |
|---|---|---|
| mRNA expression levels. | mRNA expression levels will be measured by microarray analysis. | maximum 4 weeks after the inclusion visit. |
| Measure | Description | Time Frame |
|---|---|---|
| clinical asthma profile : symptoms | symptoms | maximum 4 weeks after the inclusion visit. |
| clinical asthma profile : medical history | medical history |
Not provided
General Inclusion Criteria:
Specific inclusion criteria : asthma with proximal airways obstruction GROUP
Specific inclusion criteria : asthma with small airways dysfunction GROUP
General Exclusion Criteria:
Specific exclusion criteria :
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GILLES DEVOUASSOUX, Pr | Hospices Civils de Lyon | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cabinets de Pneumologie Liberale | Caluire-et-Cuire | France | ||||
| Hospices Civils de Lyon |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements. | Genetic | symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test. |
|
| maximum 4 weeks after the inclusion visit. |
| clinical asthma profile : date of start | date of start | maximum 4 weeks after the inclusion visit. |
| clinical asthma profile : date of aggravation | date of aggravation | maximum 4 weeks after the inclusion visit. |
| clinical asthma profile : comorbidities | comorbidities | maximum 4 weeks after the inclusion visit. |
| clinical asthma profile : increased factors related to asthma. | increased factors related to asthma. | maximum 4 weeks after the inclusion visit. |
| biological asthma profile :blood eosinophils | blood eosinophils | maximum 4 weeks after the inclusion visit. |
| biological asthma profile : blood periostin | blood periostin | maximum 4 weeks after the inclusion visit. |
| biological asthma profile : allergologic patch test | allergologic patch test | maximum 4 weeks after the inclusion visit. |
| biological asthma profile : IgE analysis | IgE analysis | maximum 4 weeks after the inclusion visit. |
| morphological asthma profile : Chest X Ray (tomodensitometric test). | Chest X Ray (tomodensitometric test). | maximum 4 weeks after the inclusion visit. |
| Lyon |
| 69002 |
| France |
| CABINETS DE PNEUMOLOGIE LIBERALE HIA Desgenettes | Lyon | France |
| HC pneumo C | Pierre-BĂ©nite | France |
| ID | Term |
|---|---|
| D001249 | Asthma |
| D002547 | Cerebral Palsy |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012130 | Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D001925 | Brain Damage, Chronic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001688 | Biological Products |
| ID | Term |
|---|---|
| D045424 | Complex Mixtures |
Not provided
Not provided